For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. argenex SE (ARGX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.argenex SE is a member of the Medical sector. This group includes 1024 individual stocks and currently holds a Zacks Sector Rank of #4. The Zac ...

argenx SE (NASDAQ:ARGX) Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Global Head of Corporate Communications & Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants James Gordon - JPMorgan Tazeen Ahmad - Bank of America Allison Bratzel - Piper Sandler Rajan Sharma - Goldman Sachs Derek Archila - Wells Fargo Akash Tewari - Jef ...

| --- | --- | --- | --- | --- | --- | --- | |-------|---------|-------|----------------------------------------------------|----------------------------|-------|-------| | | | | | | | | | | | | | | | | | Q 2 | 202 4 | | Reaching Patients through E A R N I N G S C A L L | \| J u l y 2 5 , 2 0 2 4 | | | | | | | Immunology Innovation | | | | | | | | | | | | Forward Looking Statements 2 This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any o ...

Core Insights - argenx SE reported global net product sales of $478 million in the second quarter of 2024, a significant increase from $269 million in the same period of 2023 [6][13] - The company launched VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S. following FDA approval on June 21, 2024 [5][6] - argenx aims to achieve its Vision 2030 goals, which include treating 50,000 patients globally and obtaining 10 labeled indications across its approved assets [4][22] Financial Performance - Total operating income for the second quarter of 2024 was $489 million, compared to $281 million in the same period of 2023 [11][13] - Research and development expenses increased to $225 million in Q2 2024 from $196 million in Q2 2023, reflecting ongoing investment in clinical development [12][13] - The company reported a profit of $29 million for the second quarter of 2024, a turnaround from a loss of $94 million in the same period of 2023 [16] Product Development and Pipeline - argenx is on track to initiate four additional registrational studies for efgartigimod and empasiprubart by the end of 2024 [3][22] - The company is advancing its pipeline with multiple candidates, including efgartigimod in 15 indications and empasiprubart for various autoimmune diseases [8][9] - A registrational study for VYVGART in ocular myasthenia gravis is expected to start by the end of 2024 [6][9] Regulatory Approvals and Market Expansion - VYVGART SC received approval for generalized myasthenia gravis (gMG) in China, with additional regulatory decisions expected in Switzerland, Australia, and Saudi Arabia in 2024 [6][13] - The company plans to file for regulatory approval of VYVGART SC in Canada by the end of 2024 [6][9] - Ongoing regulatory submissions for CIDP are under review in China, Japan, and Europe, with decisions anticipated in 2025 [6][9] Strategic Vision - The Vision 2030 plan includes a commitment to innovation in autoimmune disease treatment and aims to solidify argenx's leadership in FcRn biology [4][22] - The company is focused on expanding its patient reach and enhancing its product offerings through label expansions and new formulations [3][4] - argenx is investing in its Immunology Innovation Program to support the development of five new molecules in Phase 3 by 2030 [10][22]

July 18, 2024Amsterdam, the Netherlands – argenx ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argen ...

July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 25, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its half year 2024 financial results and provide a second quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.co ...

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— argenx SE ((Euronext &amp, NASDAQ:ARGX) and Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that China's National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) on July 16, 2024 for efgartigimo ...

Core Insights - Argenx SE presented new data on empasiprubart and VYVGART® Hytrulo at the 2024 Peripheral Nerve Society Annual Meeting, highlighting their potential to improve treatment outcomes for patients with multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2][3] Group 1: Empasiprubart for MMN - The Phase 2 ARDA study data supports empasiprubart as a novel treatment option for MMN, showing a 91% reduction in the risk of IVIg retreatment compared to placebo [4][10] - Empasiprubart demonstrated improvements in grip and muscle strength, enhancing patients' ability to perform daily activities [4] - The treatment was well-tolerated, with most adverse events being mild or moderate [4][13] Group 2: VYVGART Hytrulo for CIDP - VYVGART Hytrulo received FDA approval on June 21, 2024, as a safe and effective treatment for CIDP, showing a 61% reduction in the risk of relapse compared to placebo [5][7] - The ADHERE trial demonstrated sustained functional benefits across all disease scores, with 99% of participants opting for the open-label extension study [5][6] - Patients treated with VYVGART Hytrulo maintained functional improvements, while placebo patients experienced clinically meaningful worsening [6][7] Group 3: Company Overview - Argenx is focused on developing innovative therapies for severe autoimmune diseases, aiming to transform treatment outcomes and reduce the risk of relapse and disability [3][23] - The company is advancing a pipeline of antibody-based medicines, including empasiprubart and VYVGART Hytrulo, to address unmet medical needs in MMN and CIDP [3][23]

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), which is FDA approved for use in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) June 25, 2024 – 4:30pm EDT Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company comm ...

argenex SE (ARGX) shares soared 11.7% in the last trading session to close at $440.59. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.5% gain over the past four weeks.The sudden rise in the stock price was observed after the company announced that the FDA approved its subcutaneously administered Vyvgart Hytrulo (efgartigimod) for a second indication — chronic inflammatory demyelinating polyneuropathy (CIDP). The drug has been ...